Two directors of CNBX Pharmaceuticals resign effective Jan 31, 2023

CNBX Pharmaceuticals Inc.

Dr. Inbar Maymon Pomeranchik resigned as director; no disagreement with management.
Gil Feiler resigned as director; no disagreement with management.
Resignations occurred on January 31, 2023; no replacements announced.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Dr. Inbar Maymon Pomeranchik

Director and Board Member

CNBX · CNBX Pharmaceuticals Inc.

Effective: 2023-01-31
Filed: February 8, 2023, 6:59 PM ET

On January 31 st , 2023, Dr. Inbar Maymon Pomeranchik resigned from her position as a Director and Board Member.

Departed

Gil Feiler

Director and Board Member

CNBX · CNBX Pharmaceuticals Inc.

Effective: 2023-01-31
Filed: February 8, 2023, 6:59 PM ET

Also on January 31 st , 2023, Gil Feiler also presented his resignation as a Director and Board Member.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Inbar Maymon Pomeranchik resigned as Director and Board Member at CNBX Pharmaceuticals Inc..

Action: resigned
Role: Director and Board Member

Exact text from the filing

On January 31 st , 2023, Dr. Inbar Maymon Pomeranchik resigned from her position as a Director and Board Member.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Gil Feiler resigned as Director and Board Member at CNBX Pharmaceuticals Inc..

Action: resigned
Role: Director and Board Member

Exact text from the filing

Also on January 31 st , 2023, Gil Feiler also presented his resignation as a Director and Board Member.

View on SEC.gov

CNBX Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001683168-23-000628

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.